

# Ioana D Oлару

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8805061/ioana-d-olaru-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38  
papers

389  
citations

10  
h-index

19  
g-index

39  
ext. papers

552  
ext. citations

8.4  
avg, IF

3.29  
L-index

#	Paper	IF	Citations
38	"It was difficult to offer same day results": evaluation of community-based point-of-care testing for sexually transmitted infections among youth using the GeneXpert platform in Zimbabwe.. <i>BMC Health Services Research</i> , <b>2022</b> , 22, 171	2.9	0
37	Psychological distress among healthcare workers accessing occupational health services during the COVID-19 pandemic in Zimbabwe.. <i>Comprehensive Psychiatry</i> , <b>2022</b> , 116, 152321	7.3	1
36	Identifying youth at high risk for sexually transmitted infections in community-based settings using a risk prediction tool: a validation study. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 1234	4	1
35	Prevalence of ESBL-producing in adults with and without HIV presenting with urinary tract infections to primary care clinics in Zimbabwe. <i>JAC-Antimicrobial Resistance</i> , <b>2021</b> , 3, dlab082	2.9	2
34	The association between antimicrobial resistance and HIV infection: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 846-853	9.5	2
33	Risk assessment for rationalizing the use of personal protective equipment for SARS-CoV2 in healthcare settings with special focus on low- and middle-income settings. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 169-171	9.5	1
32	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	7
31	Uptake of and factors associated with testing for sexually transmitted infections in community-based settings among youth in Zimbabwe: a mixed-methods study. <i>The Lancet Child and Adolescent Health</i> , <b>2021</b> , 5, 122-132	14.5	6
30	Evaluation of the InTray and Compact Dry culture systems for the diagnosis of urinary tract infections in patients presenting to primary health clinics in Harare, Zimbabwe. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2021</b> , 40, 2543-2550	5.3	2
29	Sexually transmitted infections and prior antibiotic use as important causes for negative urine cultures among adults presenting with urinary tract infection symptoms to primary care clinics in Zimbabwe: a cross-sectional study. <i>BMJ Open</i> , <b>2021</b> , 11, e050407	3	0
28	Pathogen-free diagnosis of tuberculosis. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, 1066	25.5	
27	Fixed dose drug combinations - are they pharmaco-economically sound? Findings and implications especially for lower- and middle-income countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2020</b> , 20, 1-26	2.2	33
26	Assessment of antimicrobial use and prescribing practices among pediatric inpatients in Zimbabwe. <i>Journal of Chemotherapy</i> , <b>2020</b> , 32, 456-459	2.3	5
25	Informing the measurement of wellbeing among young people living with HIV in sub-Saharan Africa for policy evaluations: a mixed-methods systematic review. <i>Health and Quality of Life Outcomes</i> , <b>2020</b> , 18, 120	3	5
24	Antimicrobial Resistance in Gram-negative bacteria From Urinary Specimens: a study of prevalence, risk factors and molecular mechanisms of resistance (ARGUS) in Zimbabwe - a study protocol. <i>Wellcome Open Research</i> , <b>2020</b> , 5, 140	4.8	6
23	Implications of antibiotic exposure among children in low-income and middle-income countries. <i>Lancet Infectious Diseases, The</i> , <b>2020</b> , 20, 146-147	25.5	2
22	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 1205	5.6	68

21	Typhoid Vi-conjugate vaccine for outbreak control in Zimbabwe. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, 930	25.5	13
20	Evaluation of weight-based prescription of antiretroviral therapy in children. <i>HIV Medicine</i> , <b>2019</b> , 20, 248-253	2.7	3
19	Relapse-free cure from multidrug-resistant tuberculosis in Germany. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	10
18	Pulmonary Diseases in Refugees and Migrants in Europe. <i>Respiration</i> , <b>2018</b> , 95, 273-286	3.7	2
17	Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	5
16	Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis". <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	
15	What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	58
14	Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	19
13	transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	8
12	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 1489-1490	10.2	2
11	Personalized medicine for patients with MDR-TB. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 852-55.1		22
10	High Rates of Treatment Success in Pulmonary Multidrug-Resistant Tuberculosis by Individually Tailored Treatment Regimens. <i>Annals of the American Thoracic Society</i> , <b>2016</b> , 13, 1271-8	4.7	11
9	Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 1029-1031	10.2	55
8	Revisiting Healthcare Workers as a Risk Group for Progression toward Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 1021-2	10.2	0
7	Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 190, 374-83	10.2	31
6	Applying a consensus case definition to patients with confirmed tuberculous meningitis. <i>International Journal of Infectious Diseases</i> , <b>2012</b> , 16, e758-9	10.5	5
5	Reactivation of HBV infection in low grade lymphoma patient. <i>Romanian Journal of Internal Medicine</i> , <b>2011</b> , 49, 67-73		1
4	Urinary tract infection caused by carbapenem-resistant <i>K. pneumoniae</i> and <i>P. aeruginosa</i> . <i>Romanian Journal of Internal Medicine</i> , <b>2011</b> , 49, 289-94		2

- 3 A 22-gene transcriptomic model indicating individual therapy durations in multidrug-resistant tuberculosis 1
- 2 Clinical and bacteriological outcomes in patients with urinary tract infections presenting to primary care in Harare, Zimbabwe: a cohort study. *Wellcome Open Research*,6, 135 4.8
- 1 Knowledge, attitudes and practices relating to antibiotic use and resistance among prescribers from public primary healthcare facilities in Harare, Zimbabwe. *Wellcome Open Research*,6, 72 4.8